Dr Jo Brewer | VP Platform Science

Dr Jo Brewer, VP Platform Science, Adaptimmune

Jo Brewer has been with Adaptimmune since 2009,  leading teams covering research into basic T cell biology, hematopoietic stem cells, vector enhancements and translational science. She has 16 years of research experience in immunology and the biotech industry, specialising in TCRs and adoptive T cell therapy for oncology.  Prior to joining Adaptimmune, Jo previously ran the Cell Biology research group at Avidex, she holds an MA and PhD from the University of Cambridge.


Day 3 Oct 12th Immune Profiling @ 13:20

Engineering 2nd Generation SPEAR™-T cells to Overcome TGF-β-Mediated Immunosuppression

  • NY-ESO SPEAR-T cells show promise in clinical trials for solid and liquid tumours
  • Depth and durability of responses may be affected by inhibitory cytokines such as Transforming Growth Factor-β (TGF-β) in the tumour microenvironment
  • Preclinical assessment of a dominant negative TGF-β receptor (dnTGFβRII) to make T cells resistant to the inhibitory effects of TGF-β

back to speakers